Everything new and emerging for rosacea

Written by on December 28, 2023 in clinical trials, New Rosacea Treatments with 0 Comments

Dermatology and Therapy has published a lengthy article detailing emerging therapies that are on the horizon for rosacea sufferers. It may seem like new and promising treatments for rosacea are few and far between. In recent years we have seen Mirvaso, Rhofade and Soolantra approved and make their way to rosacea sufferers. More recently Zilxi and Epsolay have been offered as options for rosacea sufferers.

Emerging Medical Therapies in Rosacea: A Narrative Review has listed for us the results of a literature review from published papers and clinical trials from 2010 until August 2023. The paper gives a long list of rosacea treatment options and possibilities. Here we go.

Novel Treatments

  • Encapsulated Benzoyl Peroxide – Silica microencapsulated benzoyl peroxide 5% cream was approved by the US Food and Drug Administration (FDA) for treatment of rosacea in April 2022. The product is called Epsolay.
  • Minocycline Foam – Minocycline 1.5% foam was approved by the FDA for treatment of rosacea in May 2020, the product is called Zilxi.
  • Sarecycline – Sarecycline is a third-generation tetracycline which was approved by the FDA for the treatment of acne vulgaris in October 2018, has been used as an off label treatment for rosacea and has been trialed to evaluate as a first line rosacea treatment.
  • Ivermectin Cream – Ivermectin 1% cream was approved by the FDA for the treatment of rosacea in December 2014, the product name is Soolantra.
  • Brimonidine Tartrate 0.33% Gel – Brimonidine tartrate 0.33% gel was approved by the FDA for treatment of rosacea in August 2013, the product name is Mirvaso.
  • Oxymetazoline 1% Cream – Oxymetazoline hydrochloride 1% cream was approved by the FDA for the treatment of rosacea in January 2017, the product name is Rhofade.
  • Hydroxychloroquine – Given the role of immune dysregulation and mast cells in rosacea pathogenesis, there has been interest in whether hydroxychloroquine might be a treatment option for rosacea. “Although data are limited, hydroxychloroquine could be considered as an alternative systemic treatment option for patients who cannot achieve adequate improvement with topical therapies and would like to avoid other systemic options such as oral antibiotics or isotretinoin”
  • Intradermal Botulinum Toxin Type A – “While cost might be a limiting factor, intradermal botulinum toxin type A represents an additional potential therapeutic strategy for the management of recalcitrant redness and flushing due to rosacea.”

For more information, see their full Table 1 – Summary of novel treatments.

Clinical Pipeline Treatments

  • Topical 4% Cromolyn Sodium
  • B244 Topical Spray
  • Spongilla Powder
  • Rofumilast
  • Lotilaner Gel 2%
  • Minocycline Low-Dose, Extended-Release
  • Oral Rifaximin
  • Secukinumab
  • Erenumab

For more information see their full Table 2 – Summary of potential treatments in clinical pipeline.

Read More

Read Rosacea News on ongoing posts on new rosacea treatments.

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Follow Rosacea Support

Subscribe via RSS Feed

Leave your comment here


Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.